ClinicalTrials.gg
RecruitingNCT07214324PNRR-2022-1237Updated Nov 20, 2026

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

An observational study in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) and Multiple Myeloma (MM), sponsored by Azienda USL Reggio Emilia - IRCCS. Recruiting at 4 sites in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Azienda USL Reggio Emilia - IRCCS · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

This prospective, multicenter, observational study aims to identify molecular and immunological markers associated with disease progression in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). By integrating genomic, transcriptomic, immunophenotypic, and oral microbiome analyses, the study seeks to characterize the biological mechanisms underlying the transition to symptomatic multiple myeloma (MM). The study also includes in vitro modeling to investigate bone damage and immune dysfunction. Healthy volunteers (HV) undergoing joint replacement surgery for osteoarthritis will serve as controls. The ultimate goal is to improve early risk stratification and support future preventive strategies through a multi-omics approach. There is a pressing need for new strategies to identify high-risk individuals based on biological rather than purely clinical parameters. This study proposes an integrative, multi-omics approach to investigate the transition from MGUS/SMM to MM. By analyzing the immunome and oral microbiome alongside molecular profiling, the goal is to identify reliable biomarkers of progression. The resulting insights could be enable more accurate risk stratification and guide the design of future preventive clinical trials aimed at delaying or halting disease evolution.

Read the detailed description

Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of antibody-secreting plasma cells in the bone marrow. It accounts for approximately 10% of all blood cancers, with an incidence of 3-5per 100.000 individuals in Westen countries. MM is an incurable disease that leads to severe bone destruction and fractures due to the abnormal interaction between malignant plasma cells and the bone marrow microenvironment. Although new therapies have improved survival, MM remains a complex and genetically heterogeneous disease. Genomic instability is a hallmark of MM and includes both chromosomal abnormalities and gene mutations. Tumors may presenta s hyperdiploid - with multiple trisomies - or non-hyperdiploid, often involving translocations at the immunoglobulin heavy chain locus (IGH). These genetic differences impact prognosis. Additional recurrent alterations, such as deletions (13q, 17q), gains (1q), and mutations in genes like KRAS, NRAS, TP53, and BRAF, further illustrate the disease's biological diversity. Molecular profiling techniques, such as RNA sequencing and gene expression arrays, have identified gene expression patterns that correlate with prognosis, though only a few are currently used in clinical practice. MM is consistently preceded by two asymptomatic precursor conditions: monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). These conditions are prevalent in older adults and share many molecular features with symptomatic MM, yet only a small fraction of cases progress annually - about 1% for MGUS and 10% for SMM. Disease evolution appears to depend not only on intrinsic genetic changes but also on interactions with the bone marrow microenvironment, which includes stromal cells, dendritic cells, T cells (especially Th17), NK cells and myeloid-derived suppressors cells. Immune dysfunction, antigen presentation defects, expansion of immunosuppressive cells, and high levels of inhibitory cytokines contribute to the emergence of an immunosuppressive niche that enables myeloma cells to escape immune surveillance and progress. Immunomodulatory drugs (ImiDs) and monoclonal antibodies, which can reactivate immune responses, are therefore central to treatment strategies. Recent evidence also suggests a link between the microbiota and disease progression. In experimental models, alterations in gut microbiota have been shown to affect immune responses, influencing disease onset. Currently available prognostic tools mainly reflect tumor burden rather than underlying biology. As such, they fail to accurately predict disease progression.

02

Conditions studied

  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)
  • Multiple Myeloma (MM)

Keywords

  • plasma cells
  • multi-omics
  • biomarkers
  • bone marrow microenvironment
  • microbiome
03

In context

Monoclonal Gammopathy of Undetermined Significance

102 studies on the registry are indexed under Monoclonal Gammopathy of Undetermined Significance; 28 are open to participants now.

This study's planned enrollment of 60 is below the median of 388 across 34 observational studies indexed under Monoclonal Gammopathy of Undetermined Significance.

Browse Monoclonal Gammopathy of Undetermined Significance studies →

Lead sponsor

Azienda USL Reggio Emilia - IRCCS is the lead sponsor of 93 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients with MGUS, SMM, or MM (with or without bone lytic lesions), as well as patient with osteoarthritis undergoing joint surgery (endoprosthesis or artroplasty) (Healty Volunteers)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Male or female patients
  • confirmed diagnosis of MGUS, SMM, or MM according to ESMO 2021 guidelines
  • Willing and able to provide written

HEALTHY VOLUNTEERS (HV)

  • Age >60 years
  • Diagnosis of osteoarthritis (OA)
  • Scheduled for hospitalization for surgical treatment of OA (endoprosthesis or arthroplasty)
  • Willing and able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients:

    • Active current infection
    • disease
    • Women of unable to exclude pregnancy
    • Use of high-dose within the past 7 days, potentially affecting immunome composition

Healthy Volunteers:

  • Prior joint surgery or severe joint deformity
  • Recent trauma, osteonecrosis, or OA caused by prior/current joint infection
  • Metabolic disorders
  • Previous or current cancer diagnosis
  • Autoimmune diseases (e.g., rheumatoid arthritis)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • MGUS, SMM and MM patients

    Patients with monoclonal gammopathy of undeterminated significance, smoldering multiple myeloma, or multiple myeloma

    Other: Collection of biological material

  • Healthy volunteers

    Patients with a clinical and radiological diagnosis of osteoarthritis who undergo endo or arthro-prosthesis surgery

    Other: Collection of biological material

Interventions

  • OtherCollection of biological material

    For MGUS, SMM and MM patients, biological material (bone marrow aspirate, bone marrow biopsy, peripheral blood) consists exclusively of left-over samples obtained during routine diagnostic procedures and clinical practice management of their disease. For healthy volunteers, biological material includes waste bone tissue obtained during orthopedic surgery (endo- or arthro-prosthesis) and peripheral blood collected for research purposes. Both cohort of patient will be asked to donate gingival crevicular fluid (GCF) (this is a non-invasive procedure with no associated risks).

06

What researchers measure

Primary outcomes

  1. Bone marrow and peripheral blood immunophenotypic characterization

    Multiparametric flow cytometry of bone marrow CD138- cells and peripheral blood mononuclear cells (PBMCs) to define immune subsets and to assess alterations associated with monoclonal gammopathies progression.

    Time frame: up to 24 months

  2. Genomic and transcriptomic profiling of plasma cell

    Next-generation sequencing (NGS) analysis of bone marrow CD138+ plasma cells, including targeted 14-gene mutation panels, copy number alterations by ultra-low-pass whole genome sequencing, RNA sequencing, and single-cell transcriptomics to identify molecular signatures of disease evolution.

    Time frame: Up to 24 months

  3. Single-cell and spatial transcriptomic analyses

    Single-cell RNAseq, antibody-based sequencing (ABseq), TCR sequencing, and spatial transcriptomics on bone marrow biopsies to characterize clonal heterogeneity, cell-cell interactions, and microenvironmental influences during progression from MGUS/SMM to Multiple Myeloma.

    Time frame: up to 24 months

Secondary outcomes

  1. Evaluation of oral microbiome composition

    Sequencing-based profiling (16S rRNA) of DNA extracted from gingival crevicular fluid (GCF) samples of patients and healthy volunteers to investigate oral microbiome dysbiosis and its association with immune dysfunction and disease progression.

    Time frame: up to 24, months

  2. Functional validation of genetic profiles in osteolytic disease

    Use of CRISPR-Cas9 screening in myeloma cell lines and dynamic 3D co-culture models (osteoblasts, osteoclasts, immune and stromal cells) to evaluate the role of specific molecular pathways in osteolytic lesion development and immune impairment.

    Time frame: 24 months

07

Study locations

1 of 4 sites recruiting
  • Istituto Ortopedico Rizzoli IRCCS
    Bologna, Italy
    Active, not recruiting

    Not enrolling at this site.

  • UO Ematologia Azienda Ospedaliero-Universitaria "Policlinico Rodolico San Marco"
    Catania, Italy
    Active, not recruiting

    Not enrolling at this site.

  • UOC di Ematologia, Dipartimento di Oncologia, AOU Policlinico "Paolo Giaccone"
    Palermo, Italy
    Active, not recruiting

    Not enrolling at this site.

  • S.C Ematologia - Azienda USL IRCCS di Reggio Emilia
    Reggio Emilia, Italy
    Recruiting
08

References and documents

Publications

  • Rossi M, Altomare E, Botta C, Gallo Cantafio ME, Sarvide S, Caracciolo D, Riillo C, Gaspari M, Taverna D, Conforti F, Critelli P, Bertucci B, Iannone M, Polera N, Scumaci D, Arbitrio M, Amodio N, Di Martino MT, Paiva B, Tagliaferri P, Tassone P. miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. Leukemia. 2021 Mar;35(3):823-834. doi: 10.1038/s41375-020-0947-1. Epub 2020 Jul 6. PubMed 32632096 ↗
  • Leone P, Solimando AG, Malerba E, Fasano R, Buonavoglia A, Pappagallo F, De Re V, Argentiero A, Silvestris N, Vacca A, Racanelli V. Actors on the Scene: Immune Cells in the Myeloma Niche. Front Oncol. 2020 Oct 29;10:599098. doi: 10.3389/fonc.2020.599098. eCollection 2020. PubMed 33194767 ↗
  • Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, Martincorena I, Dawson KJ, Samur MK, Zamora J, Tarpey P, Davies H, Fulciniti M, Shammas MA, Tai YT, Magrangeas F, Moreau P, Corradini P, Anderson K, Alexandrov L, Wedge DC, Avet-Loiseau H, Campbell P, Munshi N. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018 Aug 22;9(1):3363. doi: 10.1038/s41467-018-05058-y. PubMed 30135448 ↗
  • Ziccheddu B, Da Via MC, Lionetti M, Maeda A, Morlupi S, Dugo M, Todoerti K, Oliva S, D'Agostino M, Corradini P, Landgren O, Iorio F, Pettine L, Pompa A, Manzoni M, Baldini L, Neri A, Maura F, Bolli N. Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. Clin Cancer Res. 2021 Dec 1;27(23):6479-6490. doi: 10.1158/1078-0432.CCR-20-4366. Epub 2021 Sep 15. PubMed 34526359 ↗
  • Robiou du Pont S, Cleynen A, Fontan C, Attal M, Munshi N, Corre J, Avet-Loiseau H. Genomics of Multiple Myeloma. J Clin Oncol. 2017 Mar 20;35(9):963-967. doi: 10.1200/JCO.2016.70.6705. Epub 2017 Feb 13. PubMed 28297630 ↗
  • Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012 Apr 12;12(5):335-48. doi: 10.1038/nrc3257. PubMed 22495321 ↗
  • Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011 Mar 17;364(11):1046-60. doi: 10.1056/NEJMra1011442. No abstract available. PubMed 21410373 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Aug 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 9, 2025
StartActual
Mar 17, 2025
Primary completionActual
Aug 12, 2025
CompletionEst.
Dec 31, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and contact details
1 update, last Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Minor edits only
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07214324
Lead sponsor
Azienda USL Reggio Emilia - IRCCS
Collaborators
European Union, Ministero della Salute, Italy
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Mar 17, 2025
Primary completion
Aug 12, 2025
Completion
Dec 31, 2026 (estimated)
Last update
Nov 20, 2026

Study contacts

Noemi Puccio
Contact
noemi.puccio@ausl.re.it
Antonino Neri, MD, PhD
study chair · Azienda USL Reggio Emilia - IRCCS

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion